ant3310
Small moleculeexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 12, 2023 (NCT05905913)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Beta LactamaseINHIBITOR
bla(tem-2) inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06916156 | Phase 1 | Apr 28, 2025 | Antabio, Clinartis |
| NCT06527677 | Phase 1 | Jul 19, 2024 | Antabio, University of Kiel |
| NCT05905913 | Phase 1 | Apr 12, 2023 | Antabio, Biotrial |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Antabio | For profit | 3 | 3 | 1 | 2023 |
| Biotrial | For profit | 1 | 0 | 1 | 2023 |
| Clinartis | For profit | 1 | 0 | 1 | 2025 |
| University of Kiel | Academic/Hospital | 1 | 0 | 1 | 2024 |
4 organizations
Page 1 / 1